His main research concerns Internal medicine, Myeloid leukemia, Oncology, Imatinib and Leukemia. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Surgery and Immunology. His biological study spans a wide range of topics, including Survival rate, Tet methylcytosine dioxygenase 2, Bone marrow and NPM1.
His Oncology research focuses on subjects like Discontinuation, which are linked to Ruxolitinib. His research integrates issues of Chronic myelogenous leukemia, Tyrosine kinase and Tyrosine-kinase inhibitor in his study of Imatinib. His Leukemia research incorporates themes from Myelodysplastic syndromes, Azacitidine, Hematology and Pharmacology.
Elias Jabbour mostly deals with Internal medicine, Oncology, Myeloid leukemia, Surgery and Gastroenterology. His Dasatinib, Imatinib, Cytarabine, Leukemia and Transplantation study are his primary interests in Internal medicine. His study in Dasatinib is interdisciplinary in nature, drawing from both Nilotinib and Imatinib mesylate.
The concepts of his Oncology study are interwoven with issues in Chemotherapy, Phases of clinical research, Immunology and Decitabine. His research in Myeloid leukemia intersects with topics in Myeloid, Tyrosine kinase, Cancer and Bone marrow. His work carried out in the field of Gastroenterology brings together such families of science as Vincristine, Refractory and Minimal residual disease.
His primary scientific interests are in Internal medicine, Oncology, Myeloid leukemia, Cancer research and Leukemia. Elias Jabbour performs multidisciplinary study on Internal medicine and In patient in his works. His studies in Oncology integrate themes in fields like Phases of clinical research, Cytarabine, Inotuzumab ozogamicin, Ponatinib and Transplantation.
Elias Jabbour has researched Phases of clinical research in several fields, including Gastroenterology and Azacitidine. The Myeloid leukemia study combines topics in areas such as Hematopoietic stem cell transplantation, Refractory, Tyrosine-kinase inhibitor, Bone marrow and Cohort. The study incorporates disciplines such as Myeloid and Cancer in addition to Leukemia.
Elias Jabbour focuses on Internal medicine, Oncology, Myeloid leukemia, Leukemia and Venetoclax. His work is dedicated to discovering how Internal medicine, Decitabine are connected with Clinical endpoint and other disciplines. Elias Jabbour interconnects Blinatumomab, Ponatinib, Cyclophosphamide and Phases of clinical research in the investigation of issues within Oncology.
His Myeloid leukemia study integrates concerns from other disciplines, such as Febrile neutropenia, NPM1, Cohort and Bone marrow. His Leukemia research also works with subjects such as
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille Abboud;Ellin Berman;Adam Cohen.
Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Courtney D. DiNardo;Caitlin R. Rausch;Christopher Benton;Tapan Kadia.
American Journal of Hematology (2018)
Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome.
Elias Jabbour;Hagop Kantarjian;Susan O’Brien;Jorge Cortes.
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia
Elias Jabbour;Susan O'Brien;Hagop Kantarjian;Guillermo Garcia-Manero.
Adult Acute Lymphoblastic Leukemia
Elias J. Jabbour;Stefan Faderl;Hagop M. Kantarjian.
Mayo Clinic Proceedings (2005)
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults
Nitin Jain;Kathryn G. Roberts;Elias Jabbour;Keyur Patel.
Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies.
Elias Jabbour;Jean Pierre Issa;Guillermo Garcia-Manero;Hagop Kantarjian.
Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Guillermo Garcia-Manero;Francesco Paolo Tambaro;Nebiyou B. Bekele;Hui Yang.
Journal of Clinical Oncology (2012)
Chromosomal abnormalities in Philadelphia chromosome–negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Elias Joseph Jabbour;Hagop M Kantarjian;Lynne V. Abruzzo;Susan O'Brien.
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
Elias Jabbour;Hagop Kantarjian;Dan Jones;Megan Breeden.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: